Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2018 - 2021)

Allogene Therapeutics has disclosed Long-Term Deferred Tax across 3 years of filings, most recently posting $224.3 million for Q4 2021.

• Long-Term Deferred Tax for Q4 2021 came in at $224.3 million, up 15.19% year-over-year; the trailing twelve-month figure through Dec 2021 was $224.3 million (up 15.19% YoY), and the FY2021 annual result was $224.3 million, up 15.19% from the prior year.
• Long-Term Deferred Tax came in at $224.3 million for Q4 2021 at Allogene Therapeutics, up from $194.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $224.3 million in Q4 2021 to a low of $51.8 million in Q4 2018.
• The 3-year median for Long-Term Deferred Tax is $194.7 million (2020), against an average of $156.9 million.
• Peak annual rise in Long-Term Deferred Tax reached 15.19% in 2021, while the deepest fall reached 15.19% in 2021.
• Allogene Therapeutics' Long-Term Deferred Tax stood at $51.8 million in 2018, then jumped by 275.81% to $194.7 million in 2020, then gained by 15.19% to $224.3 million in 2021.
• The last three Long-Term Deferred Tax figures came in at $224.3 million (Q4 2021), $194.7 million (Q4 2020), and $51.8 million (Q4 2018), per Business Quant data.